BioAge Labs, Inc.
BIOA evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $407.8M
- Lead Asset:
- apj programs (Preclinical)
What it means
What to watch
Prepared research question
What matters most for BIOA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIOA
BioAge Labs, Inc. (BIOA) is a biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of aging, with a lead NLRP3 inhibitor program, BGE-102.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$407.8M
Cash Runway
—
Lead Asset
apj programs (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for BioAge Labs, Inc..
BioAge Labs, Inc. (BIOA) is a biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of aging, with a lead NLRP3 inhibitor program, BGE-102.
- Lead program BGE-102 is a structurally novel, orally available small molecule NLRP3 inhibitor with brain penetration [sec · filed 2025-11-05].
- Phase 1 data for BGE-102 showed an 86% reduction in hsCRP at Day 14 and 93% of participants reaching normalized levels (<2 mg/L) [sec · filed 2026-01-12].
- Cash and equivalents of $74.0M as of 2026-06-30 [sec].
- Total revenue of $2.5M and net loss of -$26.1M as of 2026-06-30 [sec].
- Company plans to initiate a Phase 2a trial for cardiovascular risk in the first half of 2026 and a Phase 1b/2a trial for diabetic macular edema (DME) in mid-2026 [sec_mda · as of 2026-03-24].
What works
- BGE-102 demonstrated rapid and profound reduction in inflammatory markers in Phase 1, with an 86% reduction in hsCRP and favorable safety profile [sec · filed 2026-01-12].
- Company has a strong cash position of $74.0M as of 2026-06-30, providing runway for upcoming trials [sec].
- Pipeline includes multiple programs targeting cardiometabolic disease, including APJ agonists and NLRP3 inhibition, with potential to complement GLP-1 agonists [sec_mda · as of 2026-03-24].
What to weigh
- Company has no approved products and reported a net loss of -$26.1M as of 2026-06-30, with no guarantee of future profitability [sec].
- BGE-102 is still in early clinical development; full Phase 1 results are pending and Phase 2a data are not expected until year-end 2026 [sec_mda · as of 2026-03-24].
- Reliance on third-party CDMOs for manufacturing introduces operational and supply chain risks [sec_mda · as of 2024-11-07].
From the filings
Quoted directly from source documents.
BGE-102 achieved 86% reduction in hsCRP at Day 14 in Phase 1 MAD cohort
“BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L)”
SEC filings · January 12, 2026
Planned Phase 2a trial for cardiovascular risk in first half of 2026
“we intend to initiate a dose-ranging Phase 2a proof-of-concept trial in the first half of 2026 in patients with obesity and elevated hsCRP”
SEC MD&A · March 24, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has no products on the market and relies solely on future clinical success [sec_mda · as of 2024-11-07].
- Early-stage pipeline
- Manufacturing reliance — Company depends on third-party CDMOs for drug supply, which could cause delays or quality issues [sec_mda · as of 2024-11-07].
What to watch
- Full Phase 1 SAD/MAD results for BGE-102 expected in first half of 2026 [sec_mda · as of 2026-03-24].
- Initiation of Phase 2a cardiovascular risk trial for BGE-102 in first half of 2026 [sec_mda · as of 2026-03-24].
- Initiation of Phase 1b/2a DME trial for BGE-102 in mid-2026 [sec_mda · as of 2026-03-24].
- IND filings for oral and parenteral APJ programs by end of 2026 [sec_mda · as of 2025-08-06].
Sources: SEC filings · SEC MD&A · Generated September 28, 2026 · How we verify sources →
Run BioAge Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioAge Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
144
Total value held
$596.8M
| Holder | Shares | Value |
|---|---|---|
| a16z capital management, l.l.c. | 3,233,170 | $56.5M |
| cormorant asset management, lp | 2,890,605 | $50.6M |
| sofinnova investments, inc. | 2,293,788 | $40.1M |
| blackrock, inc. | 2,267,756 | $39.7M |
| janus henderson group plc | 2,094,270 | $36.6M |
| octagon capital advisors lp | 1,748,000 | $30.6M |
| ra capital management, l.p. | 1,650,648 | $28.9M |
| vanguard capital management llc | 1,354,906 | $23.7M |
| balyasny asset management l.p. | 1,327,545 | $23.2M |
| braidwell lp | 1,200,587 | $21.0M |
Showing top 10 of 144 institutional holders of BioAge Labs, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.8%
- Days to cover
- 4.4
- Shares short
- 1,884,632
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BIOA short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioAge Labs, Inc.?
BioAge Labs, Inc. (BIOA) is a biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of aging, with a lead NLRP3 inhibitor program, BGE-102.
What is BioAge Labs, Inc.'s lead drug candidate?
BioAge Labs, Inc.'s most advanced tracked candidate is apj programs (Preclinical).
Who is the CEO of BioAge Labs, Inc.?
Dr. Kristen Fortney Ph.D. is the chief executive officer of BioAge Labs, Inc. (BIOA).
Where is BioAge Labs, Inc. headquartered?
BioAge Labs, Inc. (BIOA) is headquartered in EmeryVille, CA, United States.
What therapeutic areas does BioAge Labs, Inc. focus on?
BioAge Labs, Inc. develops therapies across Ophthalmology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.